medigraphic.com
ISSN 2218-6719 (Print)

2013, Number 3

<< Back Next >>

Rev Cub de Tec de la Sal 2013; 4 (3)

Evolution clinical-hematológica of patient with syndrome sharp feverish treaties with the nutritional supplement VIUSID.

Hernández MG, Carrasco GMR, Gómez AMA, Agramonte HC, Pastor GN

Language: Spanish
References: 16
Page:
PDF size: 153.59 Kb.


ABSTRACT

Objective: Evaluate the effect and safety of the nutritional product VIUSID in the treatment of the acute febrile disease of diverse etiologic. Method: There were two groups randomly created to determine the effect of Viusid. The sample size was 200 patients, 100 in the experimental group who received conventional treatment with VIUSID and 100 in the control group receiving only conventional treatment. Both groups were evaluated in three different times (first, third and sixth day.) Results. It was found clinical improvement in all symptoms in less time and greater amount for the group taking the Viusid and better response of leukocytes Conclusions. VIUSID turned out to be effective in treating the patients with acute febrile syndrome.


REFERENCES

  1. 1- Baraff LJ. Management of fever without source in infants and children. AnnEmerg Med 2007;36:611

  2. 2- Cohen Arazi J. Síndrome Febril. Rev Med Juan P Garrán 2006; 4(32):15-18.

  3. 3- Mateos S. El laboratorio de virología clínica en el diagnóstico de infecciones respiratorias agudas bajas.Virus y Virología médica en el Uruguay, Serie de Monografías del Instituto de Higiene. Julio 2008; Nº2: 21-24

  4. 4- C.Vilar Gomez E, Gra Oramas B, Soler E, Llanio Navarro R, Ruenes Domech C. interferon alpha-2b and ribavirin in patients with chronic hepatitis Liver Int. 2007 Mar;27(2):247-59.

  5. 5- Arase Y, Ikeda K, Murashima N, et al. The long term efficacyof glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 79: 1494–500

  6. 6- Lin JC. Mechanism of action of glycyrrhizic acid in inhibition of Epstein-Barr virus replication in vitro. Antiviral Res 2005; 59: 41–47.

  7. 7- Zell R , Bergmann S, Krumbholz A, Wutzler P, Dürrwald R. Ongoing evolutionof swine influenza viruses: a novel reassortant. Arch Virol. 2008; 153(11):2085-92.-

  8. 8- Massingale y col. Emergence of a novel swine-influenza A (H1N1) virus in humans. N Engl J Med. 2009 Jun 18; 360(25):2605-15.

  9. 9- Zell R , Bergmann S, Krumbholz A, Wutzler P, Dürrwald R. Ongoing evolution of swine influenza viruses: a novel reassortant. Arch Virol. 2008; 153(11):2085-92

  10. 10- Katherine E, Arden I, Mackay M. Newly identified human rhinoviruses:molecular methods heat up the cold viruses. Rev Med Virol. 2010; 20:101-2

  11. 11- PandeminaH1N12009Actualizacaion86 http://www.who.int/csr/don/201002_ 5/en/index.html

  12. 12- Cambridge: Blackwell, Wang XQ, Li HY, Liu XY et al. The anti-respiratory syncytial virus effect of active compound of Glycyrrhiza GD4 in .vitro.Zhang Yao Cal 2006; 29: 692–694),

  13. 13- Baba M, De Cleroq S, Nakashima H, Yamamoto N. 1988. Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV). Antiviral Res 1998; 10: 289–298

  14. 14- Di Mambro VM, Fonseca MJV.Assays of physical stability and antioxidant activity of a topical formulation added with different plant extracts. J Pharm Biomed Anal. 2005; 37: 287–295

  15. 15- Wintergerst ES, Maggini S, Hornig DH. Immune-enhancingr ole of vitaminC,carotens and zinc and effect on clinical conditions.Ann Nutr Metab 2006; 50: 85–94

  16. 16- Eduardo Vilar Gomez1, Bienvenido Gra Oramas2, EnriqueArus Soler1, Raimundo Llanio Navarro3 Viusid, a nutritional supplement, in combinationwith interferon a-2b and ribavirin in patientswith chronic hepatitis. Liver International 1478-3223




2020     |     www.medigraphic.com